A standardised strategy for stopping and resuming DOAC therapy in patients with atrial fibrillation (AF) requiring elective surgery is associated with low rates of bleeding and arterial thromboembolism. The Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) study comprised 3,000 AF patients from North America and Europe who were on apixaban, dabigatran, or rivaroxaban for stroke ...
Simple perioperative DOAC strategy has good outcomes in AF
By Mardi Chapman
6 Aug 2019